Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(165 produtos)
- Bcr-Abl(117 produtos)
- EGFR(572 produtos)
- FAK(72 produtos)
- FLT(86 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(178 produtos)
- JAK(244 produtos)
- PDGFR(127 produtos)
- RAAS(86 produtos)
- Src(82 produtos)
- Syk(37 produtos)
- Trombina(56 produtos)
- VDA(2 produtos)
- VEGFR(239 produtos)
Exibir 6 mais subcategorias
Foram encontrados 2335 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
BTK-IN-10
CAS:BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).Fórmula:C25H24F2N4O2Cor e Forma:SolidPeso molecular:450.487PPD-Q
CAS:7PPD-Q is a substituted p-phenylenediamine antioxidant derivative. It exhibits toxicity towards the bacterium V. fischeri (EC50= 14.9 mg/L).Fórmula:C19H24N2O2Cor e Forma:SolidPeso molecular:312.41MK-8457
CAS:MK-8457 is a dual inhibitor of SYK and ZAP70, valuable for rheumatoid arthritis research [1].Fórmula:C24H25F3N4O3SCor e Forma:SolidPeso molecular:506.54D-69491 hydrochloride
CAS:D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.Fórmula:C25H26Cl2FN7O3Cor e Forma:SolidPeso molecular:562.42BTK-IN-15
BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.Fórmula:C28H24FN5O2Cor e Forma:SolidPeso molecular:481.52NS-062
CAS:NS-062 is an orally effective, irreversible covalent inhibitor targeting EGFR, demonstrating antiproliferative activity in the resistant double mutant H1975 cells with an IC50 of 0.19 μM. It also exhibits antitumor activity in a murine H1975 xenograft model.Fórmula:C28H30Cl2F2N6O4Cor e Forma:SolidPeso molecular:623.48VEGFR-2-IN-14
VEGFR-2-IN-14 (Compound 5) is a potent inhibitor of VEGFR-2, which inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.Fórmula:C24H23N3O3SCor e Forma:SolidPeso molecular:433.52ES-072
CAS:ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.Fórmula:C25H27F3N8O2Cor e Forma:SolidPeso molecular:528.53ALK ligand-Linker Conjugate 1
CAS:ALK ligand-Linker Conjugate 1 is an ALK ligand-connector conjugate used for the synthesis of PROTACALK degrader-4.Fórmula:C36H45N5O3Cor e Forma:SolidPeso molecular:595.77CEP-14083
CAS:CEP-14083: potent ALK inhibitor, effective in NPM/ALK T-cell lymphoma, binds ATP site; IC50=11 nmol/L, also inhibits insulin receptor, preclinical efficacy.Fórmula:C31H30N6O2Cor e Forma:SolidPeso molecular:518.61EGFR-IN-134
EGFR-IN-134 (compound 3f) is a triazolo[3,4-a]quinoline derivative and functions as a potent EGFR inhibitor with an IC50 of 0.023 µM. It induces apoptosis and necrosis in cells, and causes cell cycle arrest in the G2/M and pre-G1 phases. EGFR-IN-134 modulates the expression of apoptosis-regulating proteins by downregulating anti-apoptotic protein Bcl2 and upregulating pro-apoptotic proteins p53, Bax, and caspases 3, 8, and 9, demonstrating significant antiproliferative and anticancer activities.Fórmula:C36H30N6O5Cor e Forma:SolidPeso molecular:626.66NSC381467
CAS:NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.Fórmula:C20H16O7Cor e Forma:SolidPeso molecular:368.34VEGFR-2-IN-13
VEGFR-2-IN-13 (Compound 19a) is a potent VEGFR-2 inhibitor (IC50: 3.4 nM). vEGFR-2-IN-13 arrests the HepG2 cell cycle in G2/M phase and induces apoptosis.Fórmula:C24H18N6O2SCor e Forma:SolidPeso molecular:454.5Ersentilide
CAS:Ersentilide, a benzamide derivative, functions as both a β1-adrenergic receptor antagonist and an Ikr blocker. It has demonstrated efficacy in animal models of cardiac arrhythmias.Fórmula:C21H26N4O5SCor e Forma:SolidPeso molecular:446.52FGFR1 inhibitor-16
CAS:FGFR1inhibitor-16 (Compound 89) functions as an FGFR1 inhibitor, demonstrating an inhibition rate of 53.00% at a concentration of 50 μM and 24.95% at 10 μM. It is utilized in tumor research.Fórmula:C16H9N5O3SCor e Forma:SolidPeso molecular:351.339FAK-IN-3
FAK-IN-3 inhibits FAK, reduces PA-1 cell migration/invasion, and tumor growth, with no major side effects.
Fórmula:C28H28N6O4Cor e Forma:SolidPeso molecular:512.56SST0116CL1
CAS:SST0116CL1 is an HSP90 inhibitor (IC50: 0.21 μM) that targets the ATP-binding pocket of Hsp90, disrupting its chaperone function and leading to the degradation of client proteins (EGFR, CDK4, and AKT). It induces the degradation of Her2 in BT-474 cells (IC50: 0.2 μM) and exhibits antiproliferative activity, inhibiting tumor growth.Fórmula:C22H31ClN4O6Cor e Forma:SolidPeso molecular:482.96UNC9750
CAS:UNC9750 is an inhibitor of inositol phosphate multikinase (IPMK), with IC50 values of 31.6 nM for IPMK and 374 nM for IP6K2. It effectively suppresses the accumulation of InsP5, a direct product of IPMK kinase activity, without affecting InsP6 or InsP7 levels. Additionally, UNC9750 inhibits over 75% of the activity of four kinases: DAPK1, DYRK1B, PDGFR, and KDR. This compound is applicable in glioblastoma research.Fórmula:C23H24N6OCor e Forma:SolidPeso molecular:400.48FGFR4-IN-4
CAS:FGFR4-IN-4 is a FGFR4 inhibitor with anti-tumor activity.Fórmula:C28H32Cl2N6O5Pureza:98%Cor e Forma:SolidPeso molecular:603.5AZD0424
CAS:AZD0424: oral Src/Abl kinase inhibitor; potential anticancer; induces apoptosis, cell cycle arrest in lymphoma.Fórmula:C25H29ClN6O5Pureza:98%Cor e Forma:SolidPeso molecular:528.99
